top of page
Our Philosophy
Accelerating Innovation Through Insight and Discipline
Investing in the Engines of Biotech
VC23 invests across all biotech sectors
Our primary focus are BioTool businesses because they generally scale faster and more efficiently than other biotech sectors, typically reach revenue and partnerships earlier, and often require less capital before exit.
We also believe that the Biotool sector will continue to attract steady acquisition interest from global incumbents.
Why Venture Capital Investing Can Outperform
-
Active ownership drives alpha. VC23 is hands-on.
-
Direct access to early-stage innovation returns.
-
Diversification beyond public mega-caps.
-
Early-stage markets reward insight over consensus.
Our Work in Data
9
VC23 Active Partners & Venture Partners
7
Businesses within our active Biotools portfolio
265
Number of Biotools companies engaged in last 12 months
bottom of page